Limits...
Role of the ubiquitin-proteasome system in cardiac dysfunction of adipose triglyceride lipase-deficient mice.

Mussbacher M, Stessel H, Wölkart G, Haemmerle G, Zechner R, Mayer B, Schrammel A - J. Mol. Cell. Cardiol. (2014)

Bottom Line: Dysfunction of the UPS was accompanied by activation of NF-κB signaling.Chronic treatment of ATGL-deficient mice with the PPARα agonist Wy14,643 improved proteasomal function, prevented NF-κB activation and decreased oxidative stress.In summary, our data point to a hitherto unrecognized link between proteasomal function, PPARα signaling and cardiovascular disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology and Toxicology, University of Graz, Universitätsplatz 2, A-8010 Graz, Austria. Electronic address: marion.mussbacher@uni-graz.at.

Show MeSH

Related in: MedlinePlus

UPS and cardiac ATGL deficiency. (A) Representative Western blots of ATGL protein expression in cardiac homogenates of WT, AKO, WT/cTg, and AKO/cTg mice. Two different exposure times were chosen to better illustrate supraphysiological ATGL levels in transgene animals. (B) Representative Western blots showing total levels of ubiquitinated proteins as well as UBE1a protein expression in WT, AKO, WT/cTg, and AKO/cTg hearts. (C) Accumulation of ubiquitinated proteins was quantified in cardiac homogenates of WT (open bars), AKO (solid bars), WT/cTg (striped bars), and AKO/cTg (gray bars) mice. Total protein ubiquitination was significantly increased in ATGL deficiency. Data represent mean values ± S.E.M. of 9 individual experiments. (D) Protein expression of UBE1a was upregulated in AKO hearts. Data were expressed as folds of WT control (WT = 1) and represent mean values ± S.E.M. of 6 individual experiments. (E) Chymotrypsin-like proteasomal activity was measured in cardiac cytosols of WT (open circles) and AKO (solid circles) mice over a range of ATP concentrations (0–4 mM). Chymotrypsin-like activity was inhibited in the presence of the peptide aldehyde MG132 (1 μM). (F) Normalization of proteasomal activity to basal values (basal activity = 1) resulted in a similar activation profile. Data represent mean values ± S.E.M. of 5–6 individual experiments; *p < 0.05 vs WT. (G) Protein expression of the 19S regulatory subunit was not affected by ATGL deficiency. (H) Cardiac homogenates of AKO mice showed decreased expression of mitochondrial marker proteins citrate synthetase and prohibitin. Data were expressed as folds of WT control (WT = 1) and represent mean values ± S.E.M. of 6 individual experiments; *p < 0.05 vs WT.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4263609&req=5

f0005: UPS and cardiac ATGL deficiency. (A) Representative Western blots of ATGL protein expression in cardiac homogenates of WT, AKO, WT/cTg, and AKO/cTg mice. Two different exposure times were chosen to better illustrate supraphysiological ATGL levels in transgene animals. (B) Representative Western blots showing total levels of ubiquitinated proteins as well as UBE1a protein expression in WT, AKO, WT/cTg, and AKO/cTg hearts. (C) Accumulation of ubiquitinated proteins was quantified in cardiac homogenates of WT (open bars), AKO (solid bars), WT/cTg (striped bars), and AKO/cTg (gray bars) mice. Total protein ubiquitination was significantly increased in ATGL deficiency. Data represent mean values ± S.E.M. of 9 individual experiments. (D) Protein expression of UBE1a was upregulated in AKO hearts. Data were expressed as folds of WT control (WT = 1) and represent mean values ± S.E.M. of 6 individual experiments. (E) Chymotrypsin-like proteasomal activity was measured in cardiac cytosols of WT (open circles) and AKO (solid circles) mice over a range of ATP concentrations (0–4 mM). Chymotrypsin-like activity was inhibited in the presence of the peptide aldehyde MG132 (1 μM). (F) Normalization of proteasomal activity to basal values (basal activity = 1) resulted in a similar activation profile. Data represent mean values ± S.E.M. of 5–6 individual experiments; *p < 0.05 vs WT. (G) Protein expression of the 19S regulatory subunit was not affected by ATGL deficiency. (H) Cardiac homogenates of AKO mice showed decreased expression of mitochondrial marker proteins citrate synthetase and prohibitin. Data were expressed as folds of WT control (WT = 1) and represent mean values ± S.E.M. of 6 individual experiments; *p < 0.05 vs WT.

Mentions: Fig. 1A shows a representative Western blot of ATGL expression in cardiac homogenates of WT, AKO, WT/cTg, and AKO/cTg mice. Two different exposure times were chosen to better illustrate the massive ATGL overexpression in transgene animals (WT/cTg and AKO/cTg). To examine the involvement of UPS in the pathogenesis of cardiac dysfunction observed in AKO mice, total levels of ubiquitinated proteins as well as protein expression of the ubiquitin-activating enzyme E1 (UBE1a) were measured in cardiac homogenates of WT, AKO, WT/cTg, and AKO/cTg mice (Fig. 1B). As shown in Fig. 1C, homogenates of AKO hearts showed markedly increased levels of ubiquitinated proteins, whereas only minor accumulation was observed in WT/cTg and AKO/cTg mice compared to WT controls (Fig. 1C). Protein expression of UBE1a, which catalyzes the initial step of the UPS cascade (i.e. activation of ubiquitin moieties through thioester formation), was more than 2-fold increased in AKO hearts (Fig. 1D). Expression of UBE1a was normalized to WT levels upon cardiomyocyte-directed overexpression of ATGL in AKO mice. To investigate whether increased protein ubiquitination was a consequence of 26S proteasomal dysfunction, chymotrypsin-like activity was measured in cardiac cytosols of WT and AKO animals. Peptidase activity was monitored over a range of ATP concentrations (0–4 mM) to ensure maximal activation of the 26S proteasome. ATP bidirectionally modulated proteasomal activity with maximal activation observed at 10–30 μM ATP (Fig. 1E). Normalizing proteasomal activity to basal values (measured in the absence of exogenous ATP) resulted in a similar activation profile of the UPS in cardiac homogenates of WT and AKO mice (Fig. 1F). The selective proteasome inhibitor MG132 (1 μM) decreased chymotrypsin-like activity to a similar extent (~ 90%) in WT and AKO animals (Fig. 1E). Protein expression of the 19S regulatory cap was not affected by ATGL deficiency (Fig. 1G). Western blot analysis of the mitochondrial marker citrate synthetase revealed that protein expression was significantly decreased in AKO animals by 41 ± 8%. Similar results were obtained for prohibitin (53 ± 18%), however, results failed to reach statistical significance (Fig. 1H).


Role of the ubiquitin-proteasome system in cardiac dysfunction of adipose triglyceride lipase-deficient mice.

Mussbacher M, Stessel H, Wölkart G, Haemmerle G, Zechner R, Mayer B, Schrammel A - J. Mol. Cell. Cardiol. (2014)

UPS and cardiac ATGL deficiency. (A) Representative Western blots of ATGL protein expression in cardiac homogenates of WT, AKO, WT/cTg, and AKO/cTg mice. Two different exposure times were chosen to better illustrate supraphysiological ATGL levels in transgene animals. (B) Representative Western blots showing total levels of ubiquitinated proteins as well as UBE1a protein expression in WT, AKO, WT/cTg, and AKO/cTg hearts. (C) Accumulation of ubiquitinated proteins was quantified in cardiac homogenates of WT (open bars), AKO (solid bars), WT/cTg (striped bars), and AKO/cTg (gray bars) mice. Total protein ubiquitination was significantly increased in ATGL deficiency. Data represent mean values ± S.E.M. of 9 individual experiments. (D) Protein expression of UBE1a was upregulated in AKO hearts. Data were expressed as folds of WT control (WT = 1) and represent mean values ± S.E.M. of 6 individual experiments. (E) Chymotrypsin-like proteasomal activity was measured in cardiac cytosols of WT (open circles) and AKO (solid circles) mice over a range of ATP concentrations (0–4 mM). Chymotrypsin-like activity was inhibited in the presence of the peptide aldehyde MG132 (1 μM). (F) Normalization of proteasomal activity to basal values (basal activity = 1) resulted in a similar activation profile. Data represent mean values ± S.E.M. of 5–6 individual experiments; *p < 0.05 vs WT. (G) Protein expression of the 19S regulatory subunit was not affected by ATGL deficiency. (H) Cardiac homogenates of AKO mice showed decreased expression of mitochondrial marker proteins citrate synthetase and prohibitin. Data were expressed as folds of WT control (WT = 1) and represent mean values ± S.E.M. of 6 individual experiments; *p < 0.05 vs WT.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4263609&req=5

f0005: UPS and cardiac ATGL deficiency. (A) Representative Western blots of ATGL protein expression in cardiac homogenates of WT, AKO, WT/cTg, and AKO/cTg mice. Two different exposure times were chosen to better illustrate supraphysiological ATGL levels in transgene animals. (B) Representative Western blots showing total levels of ubiquitinated proteins as well as UBE1a protein expression in WT, AKO, WT/cTg, and AKO/cTg hearts. (C) Accumulation of ubiquitinated proteins was quantified in cardiac homogenates of WT (open bars), AKO (solid bars), WT/cTg (striped bars), and AKO/cTg (gray bars) mice. Total protein ubiquitination was significantly increased in ATGL deficiency. Data represent mean values ± S.E.M. of 9 individual experiments. (D) Protein expression of UBE1a was upregulated in AKO hearts. Data were expressed as folds of WT control (WT = 1) and represent mean values ± S.E.M. of 6 individual experiments. (E) Chymotrypsin-like proteasomal activity was measured in cardiac cytosols of WT (open circles) and AKO (solid circles) mice over a range of ATP concentrations (0–4 mM). Chymotrypsin-like activity was inhibited in the presence of the peptide aldehyde MG132 (1 μM). (F) Normalization of proteasomal activity to basal values (basal activity = 1) resulted in a similar activation profile. Data represent mean values ± S.E.M. of 5–6 individual experiments; *p < 0.05 vs WT. (G) Protein expression of the 19S regulatory subunit was not affected by ATGL deficiency. (H) Cardiac homogenates of AKO mice showed decreased expression of mitochondrial marker proteins citrate synthetase and prohibitin. Data were expressed as folds of WT control (WT = 1) and represent mean values ± S.E.M. of 6 individual experiments; *p < 0.05 vs WT.
Mentions: Fig. 1A shows a representative Western blot of ATGL expression in cardiac homogenates of WT, AKO, WT/cTg, and AKO/cTg mice. Two different exposure times were chosen to better illustrate the massive ATGL overexpression in transgene animals (WT/cTg and AKO/cTg). To examine the involvement of UPS in the pathogenesis of cardiac dysfunction observed in AKO mice, total levels of ubiquitinated proteins as well as protein expression of the ubiquitin-activating enzyme E1 (UBE1a) were measured in cardiac homogenates of WT, AKO, WT/cTg, and AKO/cTg mice (Fig. 1B). As shown in Fig. 1C, homogenates of AKO hearts showed markedly increased levels of ubiquitinated proteins, whereas only minor accumulation was observed in WT/cTg and AKO/cTg mice compared to WT controls (Fig. 1C). Protein expression of UBE1a, which catalyzes the initial step of the UPS cascade (i.e. activation of ubiquitin moieties through thioester formation), was more than 2-fold increased in AKO hearts (Fig. 1D). Expression of UBE1a was normalized to WT levels upon cardiomyocyte-directed overexpression of ATGL in AKO mice. To investigate whether increased protein ubiquitination was a consequence of 26S proteasomal dysfunction, chymotrypsin-like activity was measured in cardiac cytosols of WT and AKO animals. Peptidase activity was monitored over a range of ATP concentrations (0–4 mM) to ensure maximal activation of the 26S proteasome. ATP bidirectionally modulated proteasomal activity with maximal activation observed at 10–30 μM ATP (Fig. 1E). Normalizing proteasomal activity to basal values (measured in the absence of exogenous ATP) resulted in a similar activation profile of the UPS in cardiac homogenates of WT and AKO mice (Fig. 1F). The selective proteasome inhibitor MG132 (1 μM) decreased chymotrypsin-like activity to a similar extent (~ 90%) in WT and AKO animals (Fig. 1E). Protein expression of the 19S regulatory cap was not affected by ATGL deficiency (Fig. 1G). Western blot analysis of the mitochondrial marker citrate synthetase revealed that protein expression was significantly decreased in AKO animals by 41 ± 8%. Similar results were obtained for prohibitin (53 ± 18%), however, results failed to reach statistical significance (Fig. 1H).

Bottom Line: Dysfunction of the UPS was accompanied by activation of NF-κB signaling.Chronic treatment of ATGL-deficient mice with the PPARα agonist Wy14,643 improved proteasomal function, prevented NF-κB activation and decreased oxidative stress.In summary, our data point to a hitherto unrecognized link between proteasomal function, PPARα signaling and cardiovascular disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology and Toxicology, University of Graz, Universitätsplatz 2, A-8010 Graz, Austria. Electronic address: marion.mussbacher@uni-graz.at.

Show MeSH
Related in: MedlinePlus